Finch Therapeutics Group Inc. (FNCH) PT Lowered to $17 at Jefferies

April 4, 2022 8:15 AM EDT
Get Alerts FNCH Hot Sheet
Price: $7.30 --0%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 10 | Down: 16 | New: 19
Join SI Premium – FREE

Jefferies analyst Roger Song lowered the price target on Finch Therapeutics Group Inc. (NASDAQ: FNCH) to $17.00 (from $29.00) while maintaining a Buy rating.

The analyst commented, "Co was unable to immediately resolve the clinical hold - a variety of issues require additional alignment with the FDA (testing algorithm, protocol, manufacturing changes, etc). While all issues should be addressable, at least a quarter delay is now expected. rCDI and autism programs are on hold and HBV is now shelved. Given the uncertainty, we delay the launch and reduce program PoS to 50% - PT to $17 but remain Buy."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co, FDA